Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Advertisement · Remove ads
728 × 90
Health Tidings

Sanofi’s Sarclisa SC Gets CHMP Nod with OBI Option

CHMP recommends approval of Sarclisa SC for multiple myeloma, supported by Phase 3 IRAKLIA data showing non-inferiority to IV formulation and improved patient experience…

Written byAnand SathappanReviewed byPharmacally Editorial Team30 March 2026 · 2 min read
Fact-Checked
Gemini_Generated_Image_3o1ubs3o1ubs3o1u

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Sarclisa (isatuximab) subcutaneous (SC) formulation for patients with multiple myeloma (MM).

If approved, the SC version of Sarclisa developed by Sanofi would be available across all currently approved intravenous (IV) indications. It could become the first anticancer therapy to offer both an on-body injector (OBI) and manual injection options, and the only anti-CD38 monoclonal antibody with this dual delivery flexibility in MM.

The recommendation is primarily supported by results from the Phase 3 IRAKLIA trial (NCT05405166), which demonstrated that the SC formulation is non-inferior to the IV version in patients with relapsed or refractory multiple myeloma. Additional supporting evidence came from multiple studies, including the Phase 3 GMMG-HD8 trial (NCT05804032) and Phase 2 IZALCO (NCT05704049) and ISASOCUT studies (NCT05889221), along with a Phase 1b study in heavily pretreated patients.

Across these studies, Sarclisa SC maintained a comparable efficacy and safety profile to the IV formulation. Patient-reported outcomes showed higher satisfaction with SC administration, particularly when delivered via the OBI. Both patients and healthcare providers also expressed preference for the OBI over manual injection, highlighting potential improvements in treatment experience and convenience.

The SC formulation is administered using the enFuse® on-body delivery system developed by Enable Injections. This wearable injector is designed for high-volume subcutaneous delivery and features a thinner, retractable needle, which may enhance patient comfort compared to traditional infusion methods.

Sarclisa IV is already approved in the EU across multiple lines of therapy in both newly diagnosed and relapsed/refractory MM. A regulatory submission for the SC formulation is also under review by the U.S. Food and Drug Administration.

While the CHMP opinion represents a significant milestone, Sarclisa SC whether delivered via OBI or manual injection remains investigational until final regulatory approval is granted. A formal decision from the European Commission is expected in the coming months.

Reference

Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma, 27 March 2026, Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma

SC Versus IV Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM (IRAKLIA), ClinicalTrials.gov ID NCT05405166, https://clinicaltrials.gov/study/NCT05405166

Advertisement · Remove ads
728 × 90
Reviewed by the Pharmacally Editorial Team
Every story is checked against primary sources.
Our editorial process →